Esketamine Hydrochloride

New Platform Streamlines Path from Eligibility to Care for Patients Who Are Resistant to Standard TreatmentsSAN FRANCISCO, April 07, 2026 (GLOBE NEWSWIRE) -- Everbright Health, an AI-enabled services platform that helps mental health providers deliver advanced interventions as part of everyday care, announces its new platform to safely and effectively identify, engage, and manage care for patients who may be eligible for advanced mental health treatment options. This new, AI-enabled platform provides actionable data and insights to mental health providers about patients who may be eligible for advanced treatment options that can improve outcomes more than two-fold compared to medication and therapy alone. The platform aims to remove operational and administrative barriers to treatment options such as transcranial magnetic stimulation (TMS) and SPRAVATO® for patients with mental health conditions that are resistant to standard treatments. According to data from the National Institute of Health, nearly 60 million people in the U.S. live with a mental illness, and more than 15 million experience serious mental illness (SMI). Mental health care has historically relied on only medications and talk therapy to treat patients, but up to half of people with major mental health conditions don't get better through standard treatment options alone. For Everbright’s provider partners, the platform and specialized operational team help identify treatment-eligible patients, manage outreach and engagement, work through complex prior authorizations and billing workflows, and support the initiation and management of treatment, using proprietary AI technology and specialized human support. “More than a third of patients within the average mental health practice are eligible for advanced interventions like TMS and SPRAVATO®. But the majority of those people get missed by manual approaches for determining eligibility,” said Ben Kuhn, CEO of Everbright Health. “We use AI to navigate gaps in documentation, complex prior authorizations, and other administrative barriers that have prevented people with treatment-resistant conditions from receiving care that can be truly life-changing.” About Everbright Health Everbright Health enables mental health practices to bring advanced interventions into everyday care. The company embeds complete clinical programs – such as transcranial magnetic stimulation (TMS), SPRAVATO®, and others – into existing practices through a specialized AI-enabled services platform. Everbright provides all the infrastructure, technology, and operations required to launch, manage, and scale these programs successfully. Patients experience better outcomes, clinicians grow their practice with expanded care offerings, and payors see improved quality and lower costs – all among the millions of people with treatment resistance who need more from their mental health care. Everbright Health is a division of Careforce, Inc. For more information, visit www.everbrighthealth.com. Kate Stabrawakate@horseshoecommunications.com720-318-4080

MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company’s Board of Directors (the “Board”) from Jorey Chernett at Pointillist Family Office published on April 6, 2026: The Board and management team are committed to acting in the best interests of all shareholders and regularly evaluate opportunities to maximize shareholder value. The Board has reviewed Mr. Chernett’s letter and appreciates his engagement and dialogue as a shareholder. The Company agrees with Mr. Chernett that the current valuation does not fully reflect the strength of the Company’s business, and the Board is open to constructive engagement with its shareholders as the Company executes on its strategic priorities to enhance long-term value. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. “Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal years, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to maintain positive cash flow. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations. Investor Contact: Mike Vallie or Mark KlausnerICR Healthcare443-213-0499ir@neuronetics.com Media Contact: Devin BrodaICRDevin.Broda@icrinc.com References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.